The companies became the first to seek emergency approval for a coronavirus shot in the US last month, and the UKbegan administering their vaccine to British patientson Tuesday. The FDA granted this application Priority Review. (Reuters) - In advance of a court hearing before a federal judge in Fort Worth, Texas, Tuesday, the Food and Drug Administration has offered by the end of January to make public 12,000 pages of. Parents and caregivers can be assured that the FDA has taken a great deal of care in our review, and we encourage parents of children of any age who are eligible for primary vaccination or a bivalent COVID-19 vaccine booster dose to consider seeking vaccination now as it can potentially help protect them from COVID-19 during a time when cases are increasing.. Specifically, in the FDA's review for approval, the agency analyzed effectiveness data from approximately 20,000 vaccine and 20,000 placebo recipients ages 16 and older who did not have. The safety data accrued with the bivalent vaccine (original and omicron BA.1) and with the monovalent Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID 19 Vaccine, Bivalent because these vaccines are manufactured using the same process. Therefore, in September 2021, the scientists, represented by their attorneys at Siri & Glimstad, sued the FDA demanding it produce this data by March 2022. Before sharing sensitive information, make sure you're on a federal government site. Pfizer also did not have data on how effective the vaccine is for elderly individuals with weak immune systems or for those in frail health, according to the FDA. For the authorization of a single booster dose of the Moderna COVID-19 Vaccine, Bivalent for children 6 months through 5 years of age, the FDA relied on immune response data that it had. But Dr. Marie Griffin, an FDA advisory committee member, said the cases raise serious safety concerns. The mRNA in Comirnaty is only present in the body for a short time and is not incorporated into - nor does it alter - an individuals genetic material. More than half of the clinical trial participants were followed for safety outcomes for at least four months after the second dose. With todays authorization, the FDA has also revised the EUA of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to remove the use of the monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines for booster administration for individuals 18 years of age and older and 12 years of age and older, respectively. The monovalent Pfizer-BioNTech COVID-19 Vaccine remains authorized for administration as the first two doses of the three-dose primary series in individuals 6 months through 4 years of age, as a two-dose primary series for individuals 5 years of age and older, and as a third primary series dose for individuals 5 years of age and older who have been determined to have certain kinds of immunocompromise. In clinical trial participants 37 months through 5 years of age, other commonly reported side effects included fatigue, headache, muscle pain, joint pain, chills, and nausea/vomiting. This story has been shared 145,448 times. The most common adverse events reported for both vaccines were headaches (20%), fatigue (17%), and fever (16%). COMIRNATY (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech. In January, PfizerCEOAlbert Bourla said: We know the two-dose vaccine offers very limited protection if any. Bourla then recommended a third dose. With todays authorization, children 6 months through 4 years of age who have not yet received the third dose of the three-dose primary series with the monovalent Pfizer-BioNTech COVID-19 Vaccine will now receive the Pfizer-BioNTech COVID-19 Vaccine, Bivalent as the third dose of the primary series. January 10, 2022 A federal judge in Texas has ruled that the FDA must by the end of this month make public 12,000 pages of the data it used to make decisions about approvals for Pfizer/BioNTech's COVID-19 vaccine and then release 55,000 pages every 30 days after that until all 450,000 requested pages are public. The ending of the COVID-19 PHE will not affect the FDA's ability to authorize various products, including tests, treatments, or vaccines for emergency use. He quoted James Madison as saying a popular Government, without popular information, or the means of acquiring it, is but a Prologue to a Farce or a Tragedy and John F. Kennedy as explaining that a nation that is afraid to let its people judge the truth and falsehood in an open market is a nation that is afraid of its people.. ", However, Hannah Rosenblum, a CDC researcher and one of the study's authors, said that, overall, "Covid-19 vaccine safety monitoring is the most robust in U.S. history and the two complementary surveillance systems used in this study should bolster confidence that mRNA Covid-19 vaccines are safe. The fact sheets for both bivalent COVID-19 vaccines for recipients and caregivers and for healthcare providers include information about the potential side effects, as well as the risks of myocarditis and pericarditis. Gurtman pointed to other potential causes of the Guillain-Barre cases, noting that the man had suffered a heart attack and the woman had an upper respiratory tract infection. vaersreported 12,247 such cases. "I felt that I could vote yes at this point, with a heavy lean towards the real requirements of that post-market surveillance study," said Berger, who is also an FDA committee member. The available efficacy and safety data is from the first season. All Rights Reserved. At the time of Tuesday's meeting, there was not enough data to evaluate the effectiveness of Pfizer's vaccine against severe disease requiring hospitalization, oxygen support or a mechanical ventilator, according to the FDA. To evaluate the effectiveness of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent for individuals 12 years of age and older, the FDA analyzed immune response data among approximately 600 adults greater than 55 years of age who had previously received a 2-dose primary series and one booster dose with the monovalent Pfizer-BioNTech COVID-19 Vaccine. While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Individuals 12 years of age and older are eligible for a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. Before sharing sensitive information, make sure you're on a federal government site. Your top resources on the Covid-19 vaccines Lawsuit expedites FDA's release of vaccine data To evaluate the effectiveness of a single booster dose of the Moderna COVID-19 Vaccine, Bivalent for individuals 18 years of age and older, the FDA analyzed immune response data among approximately 600 individuals 18 years of age and older who had previously received a two-dose primary series and one booster dose of monovalent Moderna COVID-19 Vaccine. Decoupling a companys profit interest from its interest in safety creates a moral hazard and departs from centuries of product liability doctrine. "It seems to me that one case is a red flag. Pfizer's vaccine contains both strains of RSV, which circulate at the same time during fall and winter. FDA last week released 55,000 pages of review documents for Pfizer-BioNTech's Covid-19 vaccine, which some experts say may lead to "cherry picking and taking things out of context" when it comes to vaccine efficacy and safety. Key Points. The ruling follows a lawsuit filed by a nonprofit organization called Public Health and Medical Professionals for Transparency, which was formed to . Adam Berger, an official at the National Institutes of Health, said he was concerned about the Guillain-Barre cases, but said a larger study population is needed to determine whether there's an actual link to the shot. With todays authorization, the Moderna COVID-19 Vaccine, Bivalent is now authorized for administration in individuals 6 months through 5 years of age as a single booster dose at least 2 months after completion of primary vaccination with the monovalent Moderna COVID-19 Vaccine. The federal government created this unprecedented situation. Sen. Ron Johnson hosted a panel discussion in Washington, D.C., in January called COVID-19: A Second Opinion. Attorney Thomas Renz presented data from whistleblowers inside the U.S. medical system. On March 14, he said a fourth dose may be needed to fight off new variants. The safety of a single booster dose of the Moderna COVID-19 Vaccine, Bivalent for individuals 18 years of age and older is supported by safety data from a clinical study which evaluated a booster dose of Modernas investigational bivalent COVID-19 vaccine (original and omicron BA.1), safety data from clinical trials which evaluated primary and booster vaccination with the monovalent Moderna COVID-19 Vaccine, and postmarketing safety data with the monovalent Moderna COVID-19 Vaccine. A modified virus being used in fourcovid-19 vaccine contenderscalled adenovirus 5 (Ad5)has been shown to increase transmission of theaidsvirus in the past, the researchers wrote in a cautionary talepublished in theLancetmedical journal, wrote thePost. FDA staffers detailed their findings in a53-page reportahead of a Thursday meeting at which the agencys vaccine advisory committee will consider Pfizers application for an emergencyuse authorization, which could pave the way for millions of high-risk Americans to be inoculated by the end of the year. TheFDAinitially wanted to release the 200,000 pages over a period of 75 years. After one month, the immune response against BA.1 of the participants who received the bivalent vaccine was better than the immune response of those who had received the monovalent Pfizer-BioNTech COVID-19 Vaccine. Data have shown an updated COVID-19 vaccine reduces the risk of hospitalization from COVID-19 by nearly 3-fold compared to those who were previously vaccinated but have not yet received the updated vaccine. FDA last week released 55,000 pages of review documents for Pfizer-BioNTech 's Covid-19 vaccine, which some experts say may lead to "cherry picking and taking things out of context" when it comes to vaccine efficacy and safety. However, U.S. District Judge Mark Pittman of the Northern District of Texas in January issued a court order requiring FDA to significantly speed up the release of the documents. Could you provide a Link ? Data Supporting the Moderna COVID-19 Vaccine, Bivalent Authorization. Of the eight states publishing detailed, so-called breakthrough death data on the vaccinated to the present, RealClearInvestigations found that Massachusettswith a substantial 75 percent fully vaccinated ratesuffered the highest percentage of vaccinated deaths: 55 percent from January 1 to February 12. The woman has since recovered, and the man's symptoms were resolving as of the last update, according to FDA. The mRNA in these vaccines is a specific piece of genetic material that instructs cells in the body to make the distinctive spike protein of the original virus strain and the omicron variant lineages BA.4 and BA.5. A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. In the second vote, seven committee members said the vaccine effectiveness data was adequate, while four said it was not, and one member abstained. The FDAs production schedule clashed with its promise of transparency. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. A majority of the FDA committee members backed the vaccine, but they wrestled with separate votes on whether the safety and efficacy data are adequate to support an approval by the agency. When expanded it provides a list of search options that will switch the search inputs to match the current selection. The Centers for Disease Control and Prevention says the vaccines are safe and effective. The side effects listed on theCDCwebsiteare called extremely rare and include tiredness, headache, muscle pain, chills, fever and nausea. If people need to make informed decisions on vaccination, why were the 1,200 adverse effects and fatalities not released to the public until now? (D'Ambrosio, MedPage Today, 3/7; Walker, MedPage Today, 3/7), Current ArticleWhy FDA is releasing 55K pages of Covid-19 vaccine data every month. Another studyfrom theJournal of Pediatric and Adolescent Gynecologyfound that increased use of the Pfizer vaccines in kids 12 years old and over correlated with an increase in post-vaccination genital ulcers. Under the court order, FDA was required to release approximately 12,000 pages of documents immediately, and then 55,000 pages a month until all documentstotaling more than 300,000 pagesare released. The agency also couldnt say how well the vaccine works in kids younger than 16 or whether it can prevent long-term health effects of COVID-19. The FDAs excuses were incredible. The scientists explained that, until all the data is produced, a proper review cannot be conducted because missing even a single data set could throw off any analysis. Do the vaccines actually protect against infection? The FDA apparently disagreed. The FDAs approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. Originally published by our sister publication Infectious Disease Special Edition. 2023 NYP Holdings, Inc. All Rights Reserved, Government misinfo has sparked a steep decline in the publics trust, Woody Harrelson slams COVID-19 protocols on movie sets: Its not fair, Woody Harrelsons vax jab shows the Left still cant take a joke over COVID, 10 myths told by COVID experts and now debunked, began administering their vaccine to British patients, applied for an emergency use authorization. 0:40. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDAs standards for approval. Your top resources on the Covid-19 vaccines. Furthermore, data pertaining to the safety and effectiveness of the current mRNA COVID-19 vaccines, which have been administered to millions of people, including during the omicron waves of COVID-19, contributed to the agencys evaluation. As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen ) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. So did senators and representatives on both sides of the aisle. Demonstrated high efficacy againstsymptomatic COVID-19 may translate to overall prevention of transmission in populations withhigh enough vaccine uptake, the FDA scientists wrote. The FDA has more than 18,000 employees and a budget of over $6.5 billion. In a CDC study published in Lancet Infectious Diseases, researchers examined self-reported data from the Vaccine Adverse Event Reporting System (VAERS) and v-safe tracker. Sign up for free newsletters and get more CNBC delivered to your inbox. The companies became the first to seek emergency approval for a coronavirus shot in. During that period, the FDA asserts it conducted an intense, robust, and thorough analysis of those documents to assure the public that the Pfizer vaccine was safe and effective. Summary. The immune response to the booster dose of monovalent Moderna COVID-19 Vaccine in the 17 months through 5 years age group was comparable to the immune response to the two-dose primary series in the adult participants. With the release of these documents, "[t]here's a risk of cherry picking and taking things out of context," Zalewski said. Blood sample for respiratory syncytial virus (RSV) test, Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance, FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks, Novavax raises doubts about its ability to remain in business, Op-ed: DEA and FDA rules exacerbate Adderall shortage, Democratic attorneys general sue FDA to drop all remaining restrictions on abortion pill, FDA says Guillain-Barre syndrome is possible risk of Pfizers RSV vaccine for older adults, Medicare rejects Alzheimers Association request for unrestricted coverage of treatments like Leqembi, Moderna misses on earnings as costs rise from surplus production capacity, lower demand for Covid shots, West Virginia asks judge to dismiss lawsuit seeking to overturn state restrictions on abortion pill, CDC advisors recommend mpox vaccine for at-risk adults in future outbreaks, Flu vaccine was 68% effective at preventing hospitalization in children, but less protective for seniors this season, Pfizer RSV vaccine that protects infants could receive FDA approval this summer, Senators call on Medicare to offer broad coverage of Alzheimers treatments as public pressure grows, Maker of promising Alzheimers drug Leqembi expects full FDA approval this summer, expanded Medicare coverage. The Comirnaty Prescribing Information includes a warning about these risks. An official website of the United States government, Recalls, Market Withdrawals and Safety Alerts, Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose, Emergency Use Authorization for Vaccines Explained. The Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Healthhave been shown to be deeply influenced by money from pharmaceutical companies, and they are making decisions that profit themselves at the expense of public health. Individuals 18 years of age and older are eligible for a single booster dose of the Moderna COVID-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. Symptoms can range from brief weakness to paralysis. We have not lost sight that the COVID-19 public health crisis continues in the U.S. and that the public is counting on safe and effective vaccines. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. But Alejandra Gurtman, a Pfizer executive, maintained that the company did not identify any safety concerns during the trial and that the vaccine was well tolerated. The FDA wanted court approval to have up to 75 years to publicly disclose this information. Meaning, despite a reported vaccination rate of over 96% across federal health agencies back in November 2021, and the FDAs claim that the vaccines are effective, Covid-19 is still disrupting everyday life. As of Jan. 12, the FDA hasnt indicated it intends to appeal. FDA issues EUA for Novavax COVID-19 Vaccine to provide a first booster dose to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine FDA Approval - 10/19/22 What parents and caregivers need to know: Vaccines remain the best defense against the most devastating consequences of disease caused by the currently circulating omicron variant, such as hospitalization and death. Novavax COVID-19 Vaccine, Adjuvanted is available under emergency use authorization (EUA) to prevent COVID-19 in individuals 12 years of age and older. In response, the FDA produced nothing. The FDA's counterparts in Canada and the European Union are already doing it. We are confident in the evidence supporting these authorizations, said Peter Marks, M.D., Ph.D., director of the FDAs Center for Biologics Evaluation and Research. Overall, less than 1% of participants said they sought medical care for adverse events after vaccination. The FDA has determined that the available data show that the vaccine's known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older. The vote followed concerns at the FDA and among advisory committee members about two cases of Guillain-Barre syndrome in about 20,000 vaccine recipients. 0:00. Meaning that it could have taken 75 years, when most Americans alive today would be dead, to fully publicly disclose this information. Currently available data indicates that the Covid-19 vaccines from both Pfizer-BioNTech and Moderna have largely been safe for recipients. The FDA also released Pfizer and BioNTech's own 92-page analysis of the vaccine's effectiveness and safety. As Pittman recognized, America needs transparency and independent scientists to review this datanot in 75 years, but now. The mRNA is used by the body to make a mimic of one of the proteins in the virus that causes COVID-19. But several FDA advisors said there could be a . After 28 days, the immune response against BA.1 of the participants who received the bivalent vaccine was better than the immune response of those who had received the monovalent Moderna COVID-19 Vaccine. The FDA vaccine panel is scheduled to discuss Modernas COVID-19 shot at a separate meeting on Dec. 17. The Food and Drug Administration won't have 75 years to release thousands of pages of documents it relied on to license its COVID-19 vaccine. Historically, theVAERS adverse events are underreported by a factor of 100. Before the documents can be released, the agency must redact confidential business and trade secret information from Pfizer and BioNTech, as well as private patient information from clinical trials. For the authorization of a single booster dose of the Moderna COVID-19 Vaccine, Bivalent for children 6 months through 5 years of age, the FDA relied on immune response data that it had previously evaluated from a clinical study in adults of a booster dose of Modernas investigational bivalent COVID-19 vaccine that contained a component corresponding to the original strain of SARS-CoV-2 and a component corresponding to the omicron lineage BA.1. An official website of the United States government, Recalls, Market Withdrawals and Safety Alerts, Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age, Emergency Use Authorization for Vaccines Explained. Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. But it seems most people continue to place full trust in it. The risk of hospitalization increases with age, and adults ages 70 and older are more vulnerable. The .gov means its official.Federal government websites often end in .gov or .mil. The BA.4 and BA.5 lineages of the omicron variant are currently causing most cases of COVID-19 in the U.S. and are predicted to circulate this fall and winter. The FDA and CDC have confidence that this vaccine is safe and effective in preventing COVID-19. In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. Akindele, the FDA official, said real-world evidence after a vaccine rollout could answer how much protection it provides for those in fragile health. The safety data accrued with the bivalent vaccine (original and omicron BA.1) and with the monovalent Moderna COVID-19 Vaccine are relevant to the Moderna COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process. To support the FDAs approval decision today, the FDA reviewed updated data from the clinical trial which supported the EUA and included a longer duration of follow-up in a larger clinical trial population. TheNew York Postreportedon an October 2020 study that warns somecovidvaccines can increase the risk of cancer. TheFDAalso released areviewof the Moderna vaccine, which revealed post-authorization safety surveillance has identified serious risks of myocarditis and pericarditis, particularly within seven days following the second dose of Modernacovid-19 vaccine. The scientists also found the vaccine was similarly effective regardless of the recipients age, gender, race or ethnicity and among people with underlying medical issues that put them at risk for severe coronavirus infections. The FDAs attempt to close the door and lock out independent scientists from the data necessary to address these issues was irresponsible. These monovalent vaccines continue to be authorized for use for administration of a primary series for individuals 6 months of age and older as described in the letters of authorization. Of the 340,522 reports made to VAERS, 92% were non-serious, 6.6% were serious, and 1.3% were deaths. It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older . Her press release is from Thursday. CanSino Biologics Inc (CanSino Bio) claims to have secured an emergency use of authorization (EUA) from the Food and Drug Monitoring Agency (BPOM) for the recombinant COVID-19 vaccine Convidecia Air. The FDA considers such data as relevant and supportive of vaccines containing a component of the omicron variant BA.4 and BA.5 lineages. The Chinese company is also trying to mass produce and distribute the non-injectable vaccine as a heterologous booster in Indonesia. A majority of Americans are now mandated to receive a Covid-19 vaccine under penalty of losing a job, or worse. Yet, when asked to share those documents with the public, the FDA claimed it needed over 20,000 days. Information is not yet available about potential long-term health outcomes. Despite all this evidence, Big Pharma keeps moving forward with the vaccine program. The group seeks an estimated 450,000 pages of material about the vaccine-creation process during the COVID-19 pandemic that came into full force in the US in March 2020. FDA asks for 55 years to release data on Pfizer's COVID vaccine The FDA promised "full transparency" due to "tremendous public interest" in a drug that it approved after studying the data. Even more problematic is that Americans, if injured, cannot sue Pfizer. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. You can update your choices at any time in your settings. That is a rate of 1 in 34 people. But there has been no direct explanation for why this is happening. The monovalent Moderna COVID-19 Vaccine is authorized as a two-dose primary series in individuals six months of age and older and as a third primary series dose for individuals 6 months of age and older who have been determined to have certain kinds of immunocompromise. The site is secure. The data accrued with the investigational Moderna bivalent COVID-19 vaccine (original and omicron BA.1) and with the monovalent Moderna COVID-19 Vaccine are relevant to the Moderna COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process. Pfizer and BioNTech pushed the pause button Friday on the process of authorizing its COVID-19 vaccine for the youngest children. Side effects include 14,827 cases of Bells palsy, 4,377 miscarriages, 13,360 heart attacks, 37,133 cases of myocarditis/pericarditis, 13,139 shingles, and 48,342 permanently disabled. These participants received a second booster dose of either the monovalent Moderna COVID-19 Vaccine or Modernas investigational bivalent COVID-19 vaccine (original and omicron BA.1) at least 3 months after the first booster dose. The FDA analysis of data fromPfizers large-scale clinical trialinvolving roughly 44,000 people affirmed the Manhattan-based drugmakers finding that the shot was 95 percent effective at preventing COVID-19 infection aftertwo doses. For each of the bivalent COVID-19 vaccines authorized today, the FDA evaluated immunogenicity and safety data from a clinical study of a booster dose of a bivalent COVID-19 vaccine that. Based on available data, the updated, bivalent vaccines are expected to provide increased protection against COVID-19, said Peter Marks, M.D., Ph.D., director of the FDAs Center for Biologics Evaluation and Research. The safety of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent for administration as the third dose of a three-dose primary series following two doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age is based on safety data from a clinical study which evaluated a booster dose of Pfizer-BioNTechs investigational bivalent COVID-19 vaccine (original and omicron BA.1) in individuals greater than 55 years of age, safety data from clinical trials which evaluated primary vaccination in individuals 6 months of age and older with the monovalent Pfizer-BioNTech COVID-19 Vaccine, safety data from clinical trials which evaluated booster vaccination in individuals 5 years of age and older with the monovalent Pfizer-BioNTech COVID-19 Vaccine and postmarketing safety data with the monovalent Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.
Marketing Mix Of Sports Direct, Examples Of Nonconformist Behavior, Articles F